0001513160-12-000092.txt : 20121204 0001513160-12-000092.hdr.sgml : 20121204 20121204133715 ACCESSION NUMBER: 0001513160-12-000092 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121128 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20121204 DATE AS OF CHANGE: 20121204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Genesis Biopharma, Inc CENTRAL INDEX KEY: 0001425205 STANDARD INDUSTRIAL CLASSIFICATION: ARRANGEMENT OF TRANSPORTATION OF FREIGHT & CARGO [4731] IRS NUMBER: 753254381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53127 FILM NUMBER: 121240021 BUSINESS ADDRESS: STREET 1: 1601 N. SEPULVEDA BLVD., #632 CITY: MANHATTAN BEACH STATE: CA ZIP: 90266 BUSINESS PHONE: 866-963-2220 MAIL ADDRESS: STREET 1: 1601 N. SEPULVEDA BLVD., #632 CITY: MANHATTAN BEACH STATE: CA ZIP: 90266 FORMER COMPANY: FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP DATE OF NAME CHANGE: 20080128 8-K 1 currentreport.htm GENESIS BIOPHARMA CURRENT REPORT currentreport.htm

 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 8-K
 
Current Report Pursuant to Section 13 or 15(d) of the
 
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 28, 2012
 
GENESIS BIOPHARMA, INC
 
 (EXACT NAME OF COMPANY AS SPECIFIED IN ITS CHARTER)

NEVADA
 
000-53172
 
75-3254381
(STATE OR OTHER JURISDICTION OF INCORPORATION)
 
(COMMISSION FILE NUMBER)
 
(I.R.S. EMPLOYER IDENTIFICATION)

 
11500 Olympic Boulevard, Suite 400, Los Angeles CA 90064
 
(Address of principal executive offices) (Zip Code)
 
Registrant's telephone number, including area code: (866) 963-2220
 
N/A
 
(Former name or former address, if changed since last report)
 
|_| Written communication pursuant to Rule 425 under the Securities Act (17 CFR
 
230.425)
 
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
 
240.14a-12)
 
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
 
Exchange Act (17 CFR 240.14d-2(b))
 
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
 
Exchange Act (17 CFR 40.13e-4(c))
 


 
 
 

Item 5.02                      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 28, 2012, Hans Bishop, Executive Chairman of the Board of Directors of Genesis Biopharma, Inc. (the “Company”) resigned from the Company’s Board of Directors.  Mr. Bishop’s departure from the Company is due to personal reasons.  Mr. Bishop did not have any disagreements with the Company on any matter relating to the Company's operations, policies or practices.
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



GENESIS BIOPHARMA, INC.

Date: December 4, 2012
By: __/s/ Anthony J. Cataldo                                                                
Anthony J. Cataldo, Chief Executive Officer